Ensysce Biosciences, Inc. (ENSC)
Automate Your Wheel Strategy on ENSC
With Tiblio's Option Bot, you can configure your own wheel strategy including ENSC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ENSC
- Rev/Share 2.0021
- Book/Share 3.1986
- PB 1.011
- Debt/Equity 0.0844
- CurrentRatio 2.4989
- ROIC -2.2055
- MktCap 5215540.0
- FreeCF/Share -4.1407
- PFCF -0.899
- PE -0.4522
- Debt/Assets 0.0558
- DivYield 0
- ROE -1.762
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Ensysce Biosciences Bolsters Management Team with Regulatory Expert
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral
~ Advanced Preparation for New Drug Application ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for abuse and overdose, today announced it has added Tracy Hysong, CCRA as Senior Director of Regulatory Affairs to its management team. Ms. Hysong is a Certified Clinical Research Associate (CCRA) through the Association of Clinical Research Professionals with years of experience undertaking regulatory activity at the University of California Davis (UC Davis).
Read More
Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids
Published: March 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 3, 2025 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Ensysce Biosciences (NASDAQ: ENSC) CEO Dr. Lynn Kirkpatrick and Dr. Neel Pathak, DS , Program Director with Creighton University . The doctors joined TMP's host Jane King to discuss the ongoing issues with opioids for pain management and how "clever chemistry" is being used to introduce safer opioids that are less prone to accidental overdose and abuse.
Read More
About Ensysce Biosciences, Inc. (ENSC)
- IPO Date 2018-03-14
- Website https://www.ensysce.com
- Industry Biotechnology
- CEO Dr. D. Lynn Kirkpatrick Ph.D.
- Employees 7